Phase I, Double-Blind, Randomized Study of Daily, Twice-Weekly and Once-Weekly APL 2 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2018
At a glance
- Drugs APL 2 (Primary)
- Indications Dry age-related macular degeneration; Ischaemia; Paroxysmal nocturnal haemoglobinuria; Wet age-related macular degeneration
- Focus Adverse reactions; Pharmacokinetics
- 30 May 2018 The protocol has been amended to extend the study to include a total of 5 cohorts and a total of 37 subjects.
- 30 May 2018 Planned number of patients changed from 22 to 37.
- 30 May 2018 Planned End Date changed from 31 Aug 2018 to 10 Dec 2018.